Corvus Pharmaceuticals, Inc. CRVS 深 沪
等待开盘 10-28 09:30:00 美东时间
10.54
+0.090
+0.86%
华盛通- 最 高10.805
- 今 开10.49
- 成交量 113.36万股
- 最 低 10.31
- 昨 收 10.45
- 总市值 8.87亿
- 52周最高 26.95
- 市盈率 静 --
- 换手率 1.35%
- 52周最低 6.39
- 委 比 42.56%
- 总股本 8412.09万
- 历史最高 26.95
- 量 比 1.15
- 振 幅 4.74%
- 历史最低 0.607
- 每 手 1
- 风险率 3.84%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Corvus Pharmaceuticals Starts Enrollment In Its Phase 1b Clinical Study Of Soquelitinib To Treat Hidradenitis Suppurativa
Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company, today announced that enrollment has begun in its Phase 1b clinical trial of soquelitinib for the treatment of patients with hidradenitis suppurativa.
10-01 04:07
Corvus Pharmaceuticals Announces Initiation of Phase 1b Clinical Trial of Soquelitinib for Patients with Hidradenitis Suppurativa
Corvus Pharmaceuticals has initiated a Phase 1b clinical trial for soquelitinib to evaluate its safety, efficacy, and effects on Th17 biology in treating hidradenitis suppurativa (HS). The trial will enroll up to 25 patients with moderate to severe HS, receiving 200 mg twice daily for 12 weeks, followed by a 90-day follow-up. The primary endpoint is safety and tolerability, while efficacy will be measured by HiSCR 50/75 at week 12. Soquelitinib i...
09-30 20:05
Corvus Pharmaceuticals Announces Publication in Blood of Final Phase 1 Data from the Soquelitinib Phase 1/1b T Cell Lymphoma Trial
Corvus Pharmaceuticals announced the publication of Phase 1/1b trial data for soquelitinib in T cell lymphoma patients in Blood. The study showed durable responses, including complete remissions, and a median overall survival of 28.1 months. Soquelitinib selectively inhibits ITK, driving Th1 skewing and blocking Th2/Th17 differentiation. The data support ongoing Phase 3 trials in relapsed/refractory PTCL and planned trials for atopic dermatitis, ...
08-27 11:30
Corvus Pharma Q2 EPS $(0.19) Misses $(0.17) Estimate
Corvus Pharma (NASDAQ:CRVS) reported quarterly losses of $(0.19) per share which missed the analyst consensus estimate of $(0.17) by 11.76 percent. This is a 90 percent decrease over losses of $(0.10) per share from the same period last year.
08-07 04:14
Corvus Pharmaceuticals to Provide Business Update and Second Quarter 2026 Financial Results on August 6, 2026
Corvus Pharmaceuticals will host a conference call and webcast on August 6, 2026, at 4:30 pm ET (1:30 pm PT) to discuss second quarter 2026 financial results and provide a business update. Participants can join by dialing 1-800-717-1738 (US) or 1-646-307-1865 (international), or via the provided link. The webcast will also be available on the company’s investor relations website, with a replay accessible for 90 days. Corvus is a clinical-stage bi...
07-30 20:01
These latest Oppenheimer picks earn the highest Quant ratings
Oppenheimer has refreshed its OPCO Trifecta stock list, identifying companies that combine favorable fundamental ratings, positive technical trends and supportive macroeconomic tailwinds, as the firm ...
07-01 19:16
Corvus Pharma Participates In New $13.5M Financing For Angel Pharmaceuticals
Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS), a clinical-stage biopharmaceutical company, today announced that it has participated in a new $13.5 million financing for Angel Pharmaceuticals Ltd. (Angel Pharma), the
06-09 19:34
Corvus drops after early-stage trial data for eczema therapy
Corvus Pharmaceuticals (CRVS) lost ~13% on Thursday after the biotech posted final data from a Phase 1 trial for its lead candidate, soquelitinib, in patients with atopic dermatitis, an inflammatory s...
05-15 01:00
Corvus Pharmaceuticals Presents Soquelitinib Phase 1 Atopic Dermatitis Data at the Society for Investigative Dermatology (SID) Annual Meeting
Corvus Pharmaceuticals announced positive results from a Phase 1 trial of soquelitinib for moderate-to-severe atopic dermatitis. The trial showed significant clinical efficacy, including sustained remission without rebound, and a favorable safety profile. Soquelitinib inhibits ITK, reducing Th2 and Th17 cell activity while increasing Treg cells, potentially offering a novel treatment approach for autoimmune and inflammatory diseases.
05-14 11:00
